Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population
Huntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population. Blood 2016, 128: 3574. DOI: 10.1182/blood.v128.22.3574.3574.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaFirst-line therapyHealth care utilizationNon-relapse groupRelapsed diffuse large B-cell lymphomaFirst-line treatmentCare utilizationHealth care costsRelapsed cohortSTATinMED ResearchRelapsed groupMedicare beneficiariesCare costsCause health care costsHealth-care utilization analysisSignificant health care savingsHealth care resource utilizationDiffuse large B-cell lymphoma patientsHigher health care utilizationLarge B-cell lymphoma patientsB-cell lymphoma patientsOlder adultsLarge B-cell lymphomaInitial diagnosis dateNon-relapse patients